GlassScriptPhysician profile
Bethany L Dhondt
NPI 1356782619
$4,660.04
in general payments reported to CMS, 2019-2025
41 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $290 · 2021: $693 · 2022: $716 · 2023: $607 · 2024: $812 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.38 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $544.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $401.89 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $395.37 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Alkermes, INC. | $393.95 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $371.40 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $330.79 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $247.65 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lilly USA, LLC | $209.06 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Abbott Laboratories | $162.51 | 2022-2025 | Freestyle Libre |
| Teva Pharmaceuticals USA, INC. | $116.03 | 2024-2025 | Austedo Xr, Uzedy |
| Xeris Pharmaceuticals, INC. | $115.83 | 2022-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $110.01 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $105.45 | 2019-2021 | |
| Glaxosmithkline, LLC. | $103.88 | 2019-2022 | |
| Astellas Pharma US INC | $101.93 | 2019-2025 | Veozah |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Dhondt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.